Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors
FRONTIERS IN ONCOLOGY（2021）
Key words
gastrointestinal stromal tumor,resistant,ripretinib,cost-effectiveness,fourth-line or further
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined